This is the authors' abstract. We don't add key points for this paper.
Immune thrombocytopenia (ITP) is a rare but well-recognized post-allogeneic hematopoietic stem cell transplant (HSCT) autoimmune complication for which a standard treatment approach is lacking.Herein we report on an adult patient affected by high-risk acute myeloid leukemia (AML) who developed a post-HSCT ITP.Due to the refractoriness to first-line therapies the patient underwent the thrombopoietin (TPO) mimetic Eltrombopag obtaining the ITP resolution.We also discuss the clinical course of ITP in post-HSCT setting and pros and cons of different therapeutic strategies, focusing on the emerging role of TPO mimetics.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ferrarini et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: